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Available online 12 March 2008The Smith–Lemli–Opitz Syndrome (SLOS) is a congenital and developmental malformation syndrome
associated with defective cholesterol biosynthesis. SLOS is clinically diagnosed by reduced plasma levels of
cholesterol along with elevated levels of 7-dehydrocholesterol (and its positional isomer 8-
dehydrocholesterol) and the ratio of their concentrations to that of cholesterol. Since SLOS is associated
with neurological deformities and malfunction, exploring the function of neuronal receptors and their
interaction with membrane cholesterol under these conditions assumes signiﬁcance. We have earlier shown
the requirement of membrane cholesterol for the ligand binding function of an important neurotransmitter
G-protein coupled receptor, the serotonin1A receptor. In the present work, we have generated a cellular model
of SLOS using CHO cells stably expressing the human serotonin1A receptor. This was achieved bymetabolically
inhibiting the biosynthesis of cholesterol, utilizing a speciﬁc inhibitor (AY 9944) of the enzyme required in the
ﬁnal step of cholesterol biosynthesis. We utilized this cellular model to monitor the function of the human
serotonin1A receptor under SLOS-like condition. Our results show that ligand binding activity, G-protein
coupling and downstream signaling of serotonin1A receptors are impaired in SLOS-like condition, although the
membrane receptor level does not exhibit any reduction. Importantly, metabolic replenishment of cholesterol
using serum partially restored the ligand binding activity of the serotonin1A receptor. These results are
potentially useful in developing strategies for the future treatment of the disease since intake of dietary
cholesterol is the only feasible treatment for SLOS patients.
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The Smith–Lemli–Opitz Syndrome (SLOS) [1] is an autosomal
recessive disorder characterized clinically by mental retardation,
physical deformities, failure to thrive and multiple congenital
anomalies [2,3]. SLOS is caused by mutations in the gene encoding
3β-hydroxy-steroid-Δ7-reductase (7-DHCR), an enzyme required in
the ﬁnal step of cholesterol biosynthesis [4,5]. To date, close to 100
different mutations in the DHCR7 gene have been identiﬁed which
lead to the disease [6]. SLOS is ranked as one of the most serious
recessive genetic conditions [3,7]. Reduced levels of plasma choles-e-1A receptor; 5-HT1AR-EYFP,
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ll rights reserved.terol along with elevated levels of 7-dehydrocholesterol (7-DHC) (and
its positional isomer 8-dehydrocholesterol, 8-DHC) and the ratio of
their concentrations to that of cholesterol are representative para-
meters for diagnosis of SLOS [8]. Although SLOS has devastating effects
on the nervous system, the relationship of SLOS with neuronal
receptors and their membrane lipid interactions, which play a crucial
role in the function of the nervous system, remains an unexplored
area. Cholesterol is an important lipid in this context since it is known
to regulate the function of membrane receptors [9], especially
neuronal receptors [10], thereby affecting neurotransmission. Impor-
tantly, a possible role of cholesterol in a variety of neurological
disorders is well documented [11].
Previous work from our laboratory has shown the requirement of
membrane cholesterol in the function of an important neurotransmitter
receptor, the serotonin1A receptor (recently reviewed in [10]). Serotonin
receptors represent one of the largest, evolutionarily ancient, and highly
conserved families of seven transmembrane G-protein coupled recep-
tors (GPCRs) [12,13]. Among the 14 subtypes of serotonin receptors, the
G-protein coupled serotonin1A (5-HT1A) receptor is the best character-
ized for a variety of reasons [14]. Serotonin1A receptors appear to play a
key role in the generation and modulation of various cognitive,
behavioral and developmental functions such as sleep, mood, addiction,
depression, anxiety, alcohol abuse, aggression and learning [15]. This is
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serotonin1A receptor represent major classes of molecules with potential
therapeutic effects in anxiety- or stress-related disorders. Interestingly,
mutant (knockout) mice lacking the serotonin1A receptor exhibit
enhanced anxiety-related behavior, and represent an important animal
model for the analysis of complex traits such as anxiety disorders and
aggression inhigheranimals [16,17]. Keeping inmind thepharmacological
relevance of the serotonin1A receptor, which is a transmembrane protein,
its interaction with the surrounding lipid environment assumes greater
signiﬁcance in modulating its function in healthy and diseased states.
In this work, we have generated a cellular model of SLOS using CHO
cells stably expressing the human serotonin1A receptor (CHO-5-HT1AR)
by metabolically inhibiting the biosynthesis of cholesterol. To achieve
this, we utilized AY 9944, which is a speciﬁc metabolic inhibitor of 7-
DHCR [18]. AY9944 treatment results in a reduction of cholesterolwith a
concomitant accumulation of 7- and 8-DHC, thereby mimicking SLOS
(see Fig.1).We explored the function of the human serotonin1A receptor
under these conditions by monitoring ligand binding, G-protein
coupling and downstream signaling of the receptor. Our results show
that the function of the serotonin1A receptor is impaired under SLOS-like
condition. Importantly, metabolic replenishment of cholesterol partially
restored the ligand binding activity of the serotonin1A receptor. These
results are signiﬁcant since intake of dietary cholesterol is the
recommended treatment for SLOS patients.
2. Materials and methods
2.1. Materials
Cholesterol, DMPC, AY 9944, EDTA, 7-DHC, coprostanol, MgCl2, MnCl2, 8-OH-DPAT,
penicillin, streptomycin, gentamycin sulfate, polyethylenimine, PMSF, serotonin, sodium
bicarbonate, and Triswere obtained fromSigma Chemical Co. (St. Louis,MO). D-MEM/F-12
[Dulbecco's modiﬁed Eagle medium:nutrient mixture F-12 (Ham) (1:1)], lipofectamine,Fig. 1. Generation of a cellular model of Smith–Lemli–Opitz syndrome. The principal route of
the immediate precursor of cholesterol is 7-DHC. The reduction of C7(8) double bond of 7-D
NADPH-dependentmanner.Mutations in this enzyme cause SLOS, a severedevelopmental dis
cholesterol, along with elevated levels of dehydrocholesterol (7-DHC+8-DHC), have been cha
formeddue to an enzyme-catalyzed isomerization of 7-DHC. 7-DHC (and 8-DHC) differswith c
in their chemical structures). We have generated a cellular model for SLOS by treating CHO
speciﬁc metabolic inhibitor of 7-DHCR, by altering the cholesterol and dehydrocholesterol lefetal calf serum, and geneticin (G 418) were from Invitrogen Life Technologies (Carlsbad,
CA). N,O-bis(trimethylsilyl)triﬂuoroacetamide (BSTFA) was obtained from Supelco
(Bellefonte, PA). GTP-γ-S was from Roche Applied Science (Mannheim, Germany). BCA
reagent for protein estimation was from Pierce (Rockford, IL). Forskolin and IBMX were
obtained from Calbiochem (San Diego, CA). [3H]8-OH-DPAT (sp. activity=135.0 Ci/mmol)
was purchased fromDuPont New EnglandNuclear (Boston,MA). The cyclic [3H]AMPassay
kit was purchased from Amersham Biosciences (Buckinghamshire, U.K.). GF/B glass
microﬁber ﬁlters were from Whatman International (Kent, U.K.). All other chemicals and
solvents usedwere of the highest available purity. Water was puriﬁed through aMillipore
(Bedford, MA) Milli-Q system and used throughout.
2.2. Methods
2.2.1. Cell culture and treatment with AY 9944
CHOcells stably expressing thehumanserotonin1A receptor (termedasCHO-5-HT1AR)
and CHO cells stably expressing the human serotonin1A receptor tagged to enhanced
yellow ﬂuorescent protein (termed as CHO-5-HT1AR-EYFP)weremaintained inD-MEM/F-
12 (1:1) supplemented with 2.4 g/l of sodium bicarbonate, 10% fetal calf serum, 60 µg/ml
penicillin, 50 µg/ml streptomycin, 50 µg/ml gentamycin sulfate, and 200 µg/ml geneticin in
a humidiﬁed atmosphere with 5% CO2 at 37 °C. Stock solution of AY 9944 was prepared in
water and added to cells grown for 24 h (ﬁnal concentration of AY 9944was 1–10 µM) and
incubated in 5% serum for 63–66 h. Control cells were grown under similar conditions
without AY 9944 treatment.
2.2.2. Cell membrane preparation
Cell membranes were prepared as described earlier [19]. Total protein concentra-
tion in the isolated membranes was determined using the BCA assay [20].
2.2.3. Estimation of inorganic phosphate
The concentration of lipid phosphate was determined subsequent to total digestion
by perchloric acid as described earlier [21] using Na2HPO4 as standard.
2.2.4. Gas chromatography and mass spectrometry
GC–MS analysis was carried out on an Agilent 6890N gas chromatograph (Agilent
Technologies, PaloAlto, CA) equippedwith amodel 5973imass selective detector and7683
series injector. For membrane sterol measurements, cellular membranes were prepared
and total lipids were extracted in chloroform–methanol [22], after the addition of
coprostanol as an internal recovery standard. The chloroform phase obtained was driedcholesterol synthesis in humans is the Kandutsch–Russell pathway [29]. In this pathway,
HC to yield cholesterol is catalyzed by 3β-hydroxy-steroid-Δ7-reductase (7-DHCR) in an
order associatedwithmultiple congenital andmorphogenic anomalies. Reduced levels of
racterized as a diagnostic parameter of the SLOS. 8-DHC, a positional isomer of 7-DHC, is
holesterol only in a double bond at the 7th (or 8th) position in the sterol ring (highlighted
cells stably expressing the human serotonin1A receptor (CHO-5-HT1AR) with AY 9944, a
vels, thereby mimicking the condition of mutated 7-DHCR (see text for more details).
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previously [23] with somemodiﬁcations. Brieﬂy, an aliquot of the extract was hydrolyzed
in 1 M NaOH in ethanol for 1 h at 70 °C, extracted with n-hexane, and converted into
trimethylsilyl ether derivatives followed by injection into a capillary column. This was a
chemically bonded, fused silica, nonpolar CP-Sil 8CB (Varian, Middleburg, The Nether-
lands) capillary column (30 m length, 0.25 mm inner diameter, and 0.25 µm ﬁlm
thickness). To achieve optimal separation of sterols, the column oven temperature was
maintainedat 250 °Cwith a solvent delay of 5min from the timeof injection.Heliumat the
rate of 1.2 ml/min was used as the carrier gas under constant ﬂow mode. The inlet and
interface temperatures were kept at 250 and 280 °C, respectively. The ion source and
quadrupole temperatures were kept at 230 and 150 °C, respectively. Mass spectra were
scanned from 30 to 600 Da under scanmode. The ions at m/z 329, 351 and 370 were used
under Selected IonMonitoring (SIM)mode for the estimation of cholesterol, 7-DHC/8-DHC
and coprostanol, respectively. Peak areas were obtained individually for each compound
under SIMmode in the concentration range of 100–1200 ppm for cholesterol,10–100 ppm
for both 7-DHC and coprostanol, and the calibration curveswere constructed. The absolute
concentrations of various sterols in the samples were calculated from the calibration
curves. The concentration of coprostanol is used to calculate the recovery of the sterols.
Membrane sterol contents are expressed as cholesterol to total sterol ratio and cholesterol
to dehydrocholesterol (7-DHC+8-DHC) ratio.
2.2.5. Radioligand binding assays
Receptor binding assays were carried out as described earlier [19] with ~50 μg total
protein. The concentration of [3H]8-OH-DPAT in each assay tube was 0.29 nM.
2.2.6. Saturation radioligand binding assays
Saturationbindingassayswere carried outwith increasing concentrations (0.1–7.5nM)
of the radiolabeled agonist [3H]8-OH-DPAT as described previously [19,24]. The protein
content for the saturation binding assays was in the range of 75–95 μg. The dissociation
constant (Kd) andmaximum binding sites (Bmax) were calculated by non-linear regression
analysis of binding data using Graphpad Prism software version 4.00 (San Diego, CA). Data
obtained after regression analysis were used to plot graphs with the GRAFIT program
version 3.09b (Erithacus Software, Surrey, U.K.).
2.2.7. GTP-γ-S sensitivity assay
In order to estimate the efﬁciency of G-protein coupling, GTP-γ-S sensitivity assays
were carried out as described earlier [24]. The concentrations of GTP-γ-S leading to 50%Fig. 2. Identiﬁcation of sterols. Panels A and C show representative selected ion chromatogr
treated with 5 and 10 μM AY 9944, respectively. An additional peak (besides 7-DHC) was o
positional isomer of 7-DHC. Peaks 1, 2 and 3 correspond to cholesterol, 7-DHC and 8-DHC, res
8-DHC has a shorter retention time compared to 7-DHC. The distinctive patterns of m/z ratinhibition of speciﬁc agonist binding (IC50) were calculated by non-linear regression
ﬁtting of the data to a four parameter logistic function [25]:
B ¼ a= 1þ x=Ið Þs  þ b ð1Þ
where B is the speciﬁc binding of the agonist normalized to agonist binding at the lowest
concentration of GTP-γ-S, x denotes the concentration of GTP-γ-S, a is the range (ymax−
ymin) of the ﬁtted curve on the ordinate (y-axis), I is the IC50 concentration, b is the
background of the ﬁtted curve (ymin) and s is the slope factor.
2.2.8. Estimation of cyclic AMP content in cells
The ability of agonists such as 8-OH-DPAT to affect the forskolin-stimulated
increase in cAMP levels in CHO-5-HT1AR cells was assessed as described earlier [24]. The
amount of cAMP in an aliquot of the supernatant was estimated using the cyclic [3H]
AMP assay system which is based on the protein binding method described previously
[26]. Agonist dependent dose–response curves were analyzed according to the four
parameter logistic function using Eq. (1).
2.2.9. Fluorescence anisotropy measurements
Fluorescence anisotropy experiments were carried out using the ﬂuorescent probe
DPH with membranes prepared from cells that were treated with varying concentrations
of AY 9944, containing 50 nmol of total phospholipids suspended in 1.5 ml of 50mM Tris,
pH7.4 buffer, as described earlier [21]. Steady stateﬂuorescencewasmeasured in aHitachi
F-4010 spectroﬂuorometer using 1 cm path length quartz cuvettes at room temperature
(~23 °C). Excitation and emissionwavelengthswere set at 358 and 430 nm. Excitation and
emission slitswithnominal bandpassesof 1.5nmand20nmwereused. Theopticaldensity
of the samples measured at 358 nm was 0.15±0.01. The anisotropy values remained
identical evenafterdilution ofmembrane samples, indicating the absenceof any scattering
artifact [27]. Fluorescence anisotropy measurements were performed using a Hitachi
polarization accessory. Anisotropy (r) values were calculated from the equation [28]:
r ¼ IVV  GIVH
IVV þ 2GIVH ð2Þ
where IVV and IVH are themeasuredﬂuorescence intensities (after appropriate background
subtraction) with the excitation polarizer vertically oriented and the emission polarizer
vertically and horizontally oriented, respectively. G is the grating correction factor and isams of sterols obtained from total lipid extracts from membranes of CHO-5-HT1AR cells
bserved for concentrations beyond 2.5 μM of AY 9944. This was identiﬁed as 8-DHC, a
pectively. Panels B and D show themass spectra of 7-DHC and 8-DHC from lipid extracts.
ios of 7-DHC and 8-DHC are shown in panels B and D.
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light and is equal to IHV/ IHH. All experiments were donewithmultiple sets of samples and
average values of ﬂuorescence anisotropy are shown in Fig. 6.
2.2.10. Metabolic replenishment of cholesterol with serum
After treatment with 5 µM AY 9944, CHO-5-HT1AR cells were grown for 3 days in
D-MEM/F-12 (1:1) supplemented with 2.4 g/l of sodium bicarbonate, 10% fetal calf
serum, 60 μg/ml penicillin, 50 μg/ml streptomycin, 50 µg/ml gentamycin sulfate, and
200 µg/ml geneticin in a humidiﬁed atmosphere with 5% CO2 at 37 °C to achieve
metabolic replenishment of cholesterol.
2.2.11. Western blot analysis
Cell membranes were prepared from CHO-5-HT1AR-EYFP (control), AY 9944 treated
and cholesterol-replenished cells as previously described [19] with an addition of 1:20
dilution of freshly added protease inhibitor cocktail (Roche Applied Science, Mannheim,
Germany). 60 μg of total protein from each sample was mixed with 1:4 v/v of 4×
electrophoresis sample buffer and boiled for 30 min at 37 °C. Sample mixtures were
loaded and separated on 10% SDS-PAGE.
After electrophoresis, gel proteins were electrophoretically transferred to a
nitrocellulose membrane (Hybond ECL, Amersham Pharmacia Biotech, Little Chalfont,
U.K.) using semi-dry transfer apparatus (Amersham Pharmacia Biotech, Little Chalfont,
U.K.). The non speciﬁc binding sites were blocked with 10% fat-free dry milk in PBS/
Tween 20, pH 7.4 for 1 h at room temperature. To monitor the expression of 5-HT1AR-
EYFP, blots were probed with antibodies raised against GFP (BD Biosciences, San Jose,
CA; 1:10000 dilution in PBS/Tween 20), incubated overnight at 4 °C. To monitor the
levels of β-actin, which acts as a loading control, membranes were probed with
antibodies raised against β-actin (Chemicon International, Temecula, CA; diluted 1:800
in PBS/Tween 20), incubated overnight at 4 °C. Membranes were washed with PBS/
Tween 20 (washing buffer) for 30 min and the wash buffer was changed every 10 min.
Membranes were then incubated with 1:4000 dilution of a secondary antibody
(horseradish peroxidase conjugated-anti-mouse antibody) in PBS/Tween 20 for 1 h at
room temperature. Membranes were then washed and developed using the enhanced
chemiluminescence detection reagents (Amersham Biosciences, Buckinghamshire, U.K.).
5-HT1AR-EYFP and β-actin were detected using the chemiluminescence detectionFig. 3. Quantitation of sterols in membranes from CHO-5-HT1AR cells treated with AY 9944. E
5-HT1AR cells. Cholesterol and 7-DHC were identiﬁed with authentic standards. 8-DHC wa
quantitated using GC–MS analysis. Panel A shows the relative contents of membrane choles
treated with increasing concentrations of AY 9944 used, and normalized to total sterol (cho
shown in (B). The ratio of cholesterol to total sterol was normalized to control cells. The ratio
represent means±S.E. of at least three independent experiments. See Materials and methodsystem (Chemi-Smart 5000, Vilber Lourmat). 5-HT1AR-EYFP and β-actin levels were
quantitated using Bio-Proﬁle (Bio-1D+, version 11.9).
2.2.12. Statistical analysis
Signiﬁcance levels were estimated using student's two-tailed paired t-test using
Microcal Origin software version 5.0 (OriginLab Corp., Northampton, MA).
3. Results
3.1. Quantiﬁcation of sterols using gas chromatography–mass
spectrometry (GC–MS)
With an overall goal of addressing lipid–protein interactions in
healthy and diseased states, we developed a cellular model of SLOS
using AY 9944, a speciﬁc metabolic inhibitor of 7-DHCR, on CHO-5-
HT1AR cells (see Fig. 1 for more details). Sterols (cholesterol, 7-DHC
and 8-DHC) were separated, identiﬁed and quantitated using GC–MS
(Figs. 2 and 3). 7-DHC content in control cells was below the detection
level. We observed an increase in 7-DHC content up to 2.5 μM of AY
9944 (see Fig. 3A), beyond which an additional peak appeared
(Fig. 2C). This peak was identiﬁed as 8-DHC (Fig. 2C and D), a
positional isomer of 7-DHC (see Fig. 1). The identities of the
trimethylsilyl ethers of the compounds were established by compar-
ison with authentic standards for cholesterol and 7-DHC. The peak for
8-DHC was identiﬁed using its mass spectra reported earlier [30,31].
Importantly, the ratios of sterols generated using AY 9944 in these
cases (see Fig. 3) were comparable to the ratios reported in SLOS
patients [32–34]. It should be mentioned here that we estimated
phospholipid contents under identical conditions by performing lipidffect of increasing concentrations of AY 9944 on sterol content of membranes from CHO-
s identiﬁed using its mass spectra reported earlier [31,32]. Sterols were separated and
terol (gray bars), 7-DHC (open bars) and 8-DHC (hatched bars) from CHO-5-HT1AR cells
lesterol+7-DHC+8-DHC) content. The cell membrane cholesterol to total sterol ratio is
between cholesterol and total dehydrocholesterol (7-DHC+8-DHC) is shown in (C). Data
s for other details.
Fig. 4. Ligand binding function of the human serotonin1A receptor is inhibited in cellular
model of SLOS. CHO-5-HT1AR cells were treated with varying concentrations of AY 9944
and speciﬁc [3H]8-OH-DPAT binding to the serotonin1A receptor was measured (shown
in panel A). The concentration of [3H]8-OH-DPAT in each assay tubewas 0.29 nM. Values
are expressed as a percentage of speciﬁc binding for control cell membranes without AY
9944 treatment. Data shown aremeans±S.E. of at least three independent experiments.
Panel B shows saturation binding analysis of speciﬁc [3H]8-OH-DPAT binding to
serotonin1A receptors from CHO-5-HT1AR cell membranes in control (○) cells and in
cells treated with 5 µM AY 9944 (●). Representative plots are shown for speciﬁc [3H]8-
OH-DPAT binding with increasing concentrations (0.1–7.5 nM) of [3H]8-OH-DPAT under
these conditions. The curves are non-linear regression ﬁts to the experimental data
using Graphpad Prism software. See Materials and methods and Table 1 for other
details.
Table 1
Parameters for [3H]8-OH-DPAT binding in control cells and cells treated with AY 9944
Kd (nM) Bmax (pmol/mg of protein)
Control 0.26±0.04 0.65±0.03
AY 9944 treated 0.29±0.02 0.48±0.03
Binding parameters were calculated by analyzing saturation binding isotherms with a
range (0.1–7.5 nM) of the radioligand using Graphpad Prism software. The data shown in the
table representmeans±S.E. of three independent experiments. The concentration of AY 9944
used was 5 µM. See Materials and methods for other details.
Fig. 5. Reduced downstream signaling of the human serotonin1A receptor in SLOS-like
condition. The downstream signaling efﬁciency of the serotonin1A receptor was
monitored by the sensitivity of [3H]8-OH-DPAT binding to GTP-γ-S and cyclic AMP
levels. Panel A shows the effect of increasing concentrations of GTP-γ-S on the speciﬁc
binding of the agonist [3H]8-OH-DPAT to serotonin1A receptors in control cells (○) and
in cells treated with 5 µM AY 9944 (Δ). Values are expressed as percentages of the
speciﬁc binding obtained at the lowest concentration of GTP-γ-S. The curves are non-
linear regression ﬁts to the experimental data using Eq. (1). The data points represent
means±S.E. of duplicate points from at least three independent experiments. See
Materials and methods for other details. Panel B shows the estimation of cAMP levels in
CHO-5-HT1AR cells. The ability of the speciﬁc agonist (8-OH-DPAT) to reduce the
forskolin-stimulated increase in cAMP levels in control cells (○) and in cells treated
with 5 µMAY 9944 (Δ) was assessed. cAMP levels in cells were estimated as described in
Materials and methods. The curves are non-linear regression ﬁts to the experimental
data using Eq. (1). Data are normalized to cAMP levels present at the lowest
concentration of 8-OH-DPAT used in the experiment and represent the means±S.E. of
duplicate points from at least three independent experiments. See Materials and
methods for other details.
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negligible, even when the highest concentration of AY 9944 was used.
3.2. Ligand binding activity of the human serotonin1A receptor is reduced
in SLOS-like condition
Since SLOS is associated with neurological deformities andmalfunc-
tion, exploring the function of neuronal receptors and their membrane
lipid interactions under these conditions assumes signiﬁcance. We
explored the ligand binding function of the human serotonin1A receptor
under SLOS-like condition. Fig. 4A shows the effect of AY 9944 treatment
on speciﬁc [3H]8-OH-DPAT binding to serotonin1A receptors in CHO-5-
HT1AR cells. As shown in the ﬁgure, there is a progressive and drastic
reduction in the speciﬁc [3H]8-OH-DPAT binding with increasing
concentrations of AY 9944 used. The reduction in agonist binding
correlates well with the reduction in ratio between cholesterol to total
sterol as well as the cholesterol to dehydrocholesterol ratio (shown in
Fig. 3B and C). The agonist binding of the human serotonin1A receptor is
reduced to ~8% of the original value upon treatment with 10 μM AY
9944. Importantly, the reduction in agonist binding is not due to a
decrease in the expression level of the human serotonin1A receptor (see
later, Fig. 8). Although the requirement of membrane cholesterol in
maintaining the ligand binding activity of the serotonin1A receptor haspreviously been reported by us [35], this result represents the ﬁrst
observation that defective cholesterol biosynthesis could result in loss of
speciﬁc agonist binding to the serotonin1A receptor.
The saturation binding analysis of the speciﬁc agonist [3H]8-OH-
DPAT binding to serotonin1A receptors is shown in Fig. 4B and Table 1.
The results of saturation binding analysis with the agonist [3H]8-OH-
DPAT, carried out with membranes prepared from AY 9944 treated
and control cells, revealed that the reduction in ligand binding can
Fig. 6. Overall membrane order is unaltered in SLOS-like condition. The overall
(average) membrane order was estimated in control cell membranes and in membranes
of cells treated with varying concentrations of AY 9944, using ﬂuorescence anisotropy of
the membrane probe DPH. Fluorescence anisotropy measurements were carried out
with membranes containing 50 nmol phospholipid at a probe to phospholipid ratio of
1:100 (mol/mol) at room temperature (~23 °C). Data represent means±S.E. of duplicate
points from at least three independent experiments. See Materials and methods for
other details.
Fig. 7. Metabolic replenishment of cholesterol with serum. After treatment with 5 μM
AY 9944, CHO-5-HT1AR cells were allowed to recover by metabolic replenishment with
serum cholesterol. Following AY 9944 treatment, cellswere grown for 3 days in D-MEM/F-12
(1:1) medium (supplemented with 2.4 g/l of sodium bicarbonate, 10% fetal calf serum,
60 µg/ml penicillin, 50 µg/ml streptomycin, 50 µg/ml gentamycin sulfate, and 200 µg/ml
geneticin) in a humidiﬁed atmosphere with 5% CO2 at 37 °C, sterols were extracted from
cell membranes and quantiﬁed using GC–MS. Panel A shows the relative contents of
membrane cholesterol (gray bars), 7-DHC (open bars) and 8-DHC (hatched bars) in
control (without AY 9944 treatment) cells, AY 9944 treated cells and cells in which
cholesterol was metabolically replenished. The relative sterol contents are normalized
to total sterol (cholesterol+7-DHC+8-DHC) content. The corresponding changes in the
speciﬁc binding of the agonist [3H]8-OH-DPAT to serotonin1A receptors under these
conditions are shown in (B). See Materials and methods for other details.
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sites with a marginal reduction in the afﬁnity of ligand binding. There
is a signiﬁcant reduction (~26%, pb0.02) in the maximum number of
binding sites (Bmax) when the CHO-5-HT1AR cells were treated with
5 μM AY 9944.
3.3. Ligand-dependent downstream signaling efﬁciency of the human
serotonin1A receptor is reduced in SLOS-like condition
Most of the seven transmembrane domain receptors are coupled to
G-proteins, and therefore guanine nucleotides are known to modulate
ligand binding. The serotonin1A receptor agonists such as 8-OH-DPAT are
known to speciﬁcally activate the Gi/Go class of G-proteins in CHO cells
[36]. Agonist binding to such receptors therefore displays sensitivity to
agents such as GTP-γ-S, a non-hydrolyzable analogue of GTP, that un-
couple the normal cycle of guanine nucleotide exchange at the Gα subunit
caused by receptor activation. We have previously shown that in the
presence of GTP-γ-S, serotonin1A receptors undergo an afﬁnity transi-
tion, from a high afﬁnity G-protein coupled to a low-afﬁnity G-protein
uncoupled state [37]. In agreement with these results, Fig. 5A shows a
characteristic reduction in binding of the agonist [3H]8-OH-DPAT in
the presence of a range of concentrations of GTP-γ-Swith an estimated
half maximal inhibition concentration (IC50) of 3.75 nM for control
cells. The inhibition curve in case of cells treatedwith AY 9944 displays
a signiﬁcant (~2.5-fold, pb0.03) shift toward higher concentrations of
GTP-γ-S with an increased IC50 value of 9.92 nM. This implies that the
agonist binding to the serotonin1A receptor in SLOS-like condition is
less sensitive to GTP-γ-S indicating that the G-protein coupling
efﬁciency is reduced under these conditions. This suggests a possible
perturbation of receptor-G-protein interaction in SLOS-like condition.
In addition to ligand binding properties, we monitored the
function of serotonin1A receptors in CHO-5-HT1AR cells bymeasuring
its ability to catalyze downstream signal transductionprocesses upon
stimulation with the speciﬁc agonist, 8-OH-DPAT. Serotonin1A
receptor agonists such as 8-OH-DPAT are known to speciﬁcally
activate the Gi/Go class of G-proteins in CHO cells, which subsequently
reduce cAMP levels in cells [36]. As shown in Fig. 5B, the forskolin-
stimulated increase in cAMP levels is inhibited by8-OH-DPATwith a half
maximal inhibition concentration (IC50) of 11.97 nM in control cells. In
cells treated with AY 9944, the IC50 value is increased to a considerable
extent (~4-fold, pb0.13) to 50.68 nM. This points out that the
downstream signaling efﬁciency of the human serotonin1A receptor is
considerably reduced under this condition.3.4. Reduction in the function of the human serotonin1A receptor in
SLOS-like condition is independent of the overall membrane order
In order to explore any possible change in overall membrane
order upon AY 9944 treatment, we measured the ﬂuorescence
anisotropy of the ﬂuorescent probe DPH. Fluorescence anisotropy
measured using probes such as DPH is correlated to the rotational
diffusion of membrane embedded probes [28], which is sensitive to
the packing of lipid fatty acyl chains. This is due to the fact that
ﬂuorescence anisotropy depends on the degree to which the probe
is able to reorient after excitation, and probe reorientation is a
function of local lipid packing. DPH, which is a rod-like hydrophobic
molecule, partitions into the interior (fatty acyl chain region) of the
bilayer. Fig. 6 shows the effect of increasing concentrations of AY
9944 on the ﬂuorescence anisotropy of the membrane probe DPH
incorporated into CHO-5-HT1AR cell membranes. The ﬂuorescence
anisotropy of DPH appears to be more or less invariant over the
concentration range of AY 9944 used. These results therefore
suggest that the overall (global) membrane order is not signiﬁcantly
altered in SLOS-like condition and changes in ligand binding
activity and downstream signaling could be due to speciﬁc (local)
effects (see later).
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activity of the human serotonin1A receptor
Treatmentof SLOS consists of reduction of 7-DHC levels on onehand,
and to supplement deﬁcient cholesterol, on the other hand. This is
generally achieved by providing supplemental cholesterol in the diet
[7,38,39]. This is due to the fact that the supplemented dietary
cholesterol would reduce cholesterol precursors by feedback inhibition
of HMG-CoA reductase. In order to check the reversibility of the changes
induced by AY 9944 (i.e., reduction of cholesterol and accumulation of
dehydrocholesterol) in SLOS-like condition in CHO-5-HT1AR cells, we
performed metabolic replenishment with serum cholesterol. This was
carried out by incubating cells treated with AY 9944 for 3 days in serum
(see Materials and methods). Under these conditions, a signiﬁcant
(pb0.01) fraction of cholesterol could be restored, along with a
concomitant reduction in 8-DHC levels, and an overall decrease in
combined dehydrocholesterol levels (Fig. 7A), resulting in signiﬁcant
(pb0.01) recovery of the ligand binding activity (see Fig. 7B).
3.6. The expression level of the serotonin1A receptor is not reduced in
SLOS-like condition
The impaired ligand binding activity and signaling of the human
serotonin1A receptor observed in SLOS-like condition could be due to
reduced expression levels of serotonin1A receptors. In order to explore
this possibility, we performedWestern blot analysis of 5-HT1AR-EYFP in
cellmembranes prepared fromcontrol, AY9944 treatedand cholesterol-
replenished CHO-5-HT1AR-EYFP cells (see Fig. 8). For these experiments,
we chose to use the receptor tagged to EYFP (5-HT1AR-EYFP) since no
monoclonal antibodies for the serotonin1A receptor are availableyet, andFig. 8. The expression level of the human serotonin1A receptor is not reduced in
membranes of cellular model of SLOS. Western blot analysis of 5-HT1AR-EYFP in
membranes prepared from CHO-5-HT1AR-EYFP (control) cells, CHO-5-HT1AR-EYFP cells
treated with 5 μM AY 9944 and after metabolic replenishment with serum cholesterol.
Panel A shows the human serotonin1A receptor tagged to EYFPwith corresponding β-actin
probed with antibodies directed against GFP and β-actin. Panel B shows the
quantitation of 5-HT1AR-EYFP and β-actin levels using densitometry. 5-HT1AR-EYFP
levels were normalized to β-actin of the corresponding sample. Data are shown as fold
increase of 5-HT1AR-EYFP over control and represent means±S.E. of at least four
independent experiments. See Materials and methods for other details.the polyclonal antibodies have been reported to give variable results
onWestern blots [40]. We have earlier shown that EYFP fusion to the
serotonin1A receptor does not affect the ligand binding properties,
G-protein coupling and signaling functions of the receptor [41]. Fig. 8B
shows that the levels of the serotonin1A receptor in membranes are not
reduced in SLOS-like condition. The receptor level is slightly increased
(~1.4-fold compared to control) following AY 9944 treatment. This
increase, however, was found to be not signiﬁcant (pN0.05). After
metabolic replenishment with serum cholesterol, the receptor level
increased to ~1.6-fold. It has been previously reported that serotonin1A
receptor levels in CHO cells could increase upon induction of stress [42].
4. Discussion
SLOS is a congenital and developmental malformation syndrome
associated with defective cholesterol biosynthesis. Patients diagnosed
with SLOS typically showgrowth andmental retardation,microcephaly,
cleft palate, syndactyly, urogenital abnormalities, and a variety of other
anatomical defects. SLOS is clinically characterized by reduced levels of
plasma cholesterol coupled with accumulation of 7- and 8-DHC.
Learning disabilities and mental retardation are present in at least 95%
of SLOS patients [38] which could be attributed to impaired neuro-
transmission. The relationship between clinical severity and biochem-
ical parameters in SLOS is an ongoing area of research. It has been
reported previously that reduced cholesterol levels are associated with
increased clinical severity, while the correlation between 7-DHC and
clinical severity is weak [43]. These results are supported using SLOS
animal model, which shows that cholesterol deﬁcit but not accumula-
tion of precursor sterols, is the major cause of abnormal embryogenesis
in SLOS [44]. Importantly, cholesterol is an essential lipid in this context
since a number of neurological diseases share a common etiology of
defective cholesterolmetabolism in the brain [45]. Asmentioned earlier,
we have previously shown the requirement of membrane cholesterol in
the function of the serotonin1A receptor [10,35]. Based on this evidence,
it appears that reduction in cholesterol levels could contribute to the
impairment of function of the serotonin1A receptor under SLOS-like
condition, although effects of accumulation of dehydrocholesterol may
not be ruled out.
Serotonin1A receptors are members of a superfamily of seven
transmembrane domain receptors [46] that couple to and transduce
signals via G-proteins [14]. In this work, we havemonitored the effect of
metabolic inhibition of cholesterol biosynthesis on the function of the
human serotonin1A receptor in CHO-5-HT1AR cells. These results show
that ligand binding activity, G-protein coupling and downstream
signaling of serotonin1A receptors are impaired in SLOS-like condition.
The potential clinical relevance of this observation stems from the fact
that defective cholesterol biosynthesis constitutes a common theme for
a number of genetically inherited disorders [47]. These results assume
greater signiﬁcance in the light of recent ﬁndings that symptoms of
anxiety and major depression are apparent in humans upon long term
administration of statinswhich are inhibitors of the ﬁrst enzyme (HMG-
CoA reductase) in the cholesterol biosynthesis pathway [48]. Interest-
ingly, SLOS carriers have been reported to be at greater risk of suicidal
behavior [49] and a recent study has shown that serotonin1A receptors
play a key role in the biology of suicidal behavior [50].
Importantly, our results show that the receptor level is not reduced
under this condition. This implies that the fraction of functional re-
ceptors is reduceduponAY 9944 treatment resulting in a higher fraction
of non-functional receptors. Interestingly, these results could be related
to an earlier report describing abnormal development of serotonergic
neurons in SLOS mouse model [51]. In addition, modulation of
serotonergic transmission has been implicated in cholesterol-lowering
therapy [52]. Our results assume signiﬁcance in the light of the fact that
SLOS patients suffer from impaired neurotransmission. It should be
mentioned here that although we have monitored the levels of mem-
brane sterols and clinical reports from patient samples rely on plasma
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plasma sterols are positively correlated [53]. Based on our results, it
could be possible that the function of serotonin1A receptors is reduced in
SLOS patients, since themembrane sterol levelswe obtainedmatchwell
with reported serum sterol levels in SLOS patients [32–34]. Clearly,
further work is needed in this area to support this hypothesis.
The effect of cholesterol on the structure and function of integral
membrane proteins has been a subject of intense investigation [9,10]. It
has been proposed that such effects could occur either due to a speciﬁc
molecular interactionwithmembrane proteins [54], or due to alterations
in the membrane physical properties induced by the presence of
cholesterol [55,56], or due to a combination of both factors. We have
earlier shown that oxidation of membrane cholesterol with cholesterol
oxidase leads to inhibitionof the ligandbinding activityof the serotonin1A
receptor [57]. In the present work, we have utilized a cellular model of
SLOS in order to delineate the speciﬁc and global effects of cholesterol in
the function of the serotonin1A receptor. SLOS serves as an appropriate
condition to test this since the two aberrant sterols that get accumulated
in SLOS, i.e., 7- and 8-DHC, differ with cholesterol only in a double bond.
Our results show that the overallmembrane order, asmonitoredwith the
ﬂuorescent probe DPH, does not exhibit signiﬁcant change in SLOS-like
condition (Fig. 6). Interestingly, we have recently shown that 7-DHC does
not support the function of the serotonin1A receptor without any change
in overall membrane order [58]. We therefore conclude that the
requirement for maintaining ligand binding activity is more stringent
than the requirement for maintaining membrane order. Taken together,
these results indicate that the molecular basis for the requirement of
membrane cholesterol in maintaining the ligand binding activity of
serotonin1A receptors could be speciﬁc interaction, although global
bilayer effects may not be ruled out.
Cholesterol is an essential component of eukaryotic membranes and
plays a crucial role in membrane organization, dynamics, function and
sorting. It is often found distributed non-randomly in domains or pools
in biological membranes [59,60]. Many of these domains (sometimes
termed as ‘lipid rafts’) are believed to be important for themaintenance
of membrane structure and function, although characterizing the
spatiotemporal resolution of these domains is proving to be challenging
[60,61]. The idea of such membrane domains gains signiﬁcance since
physiologically important functions such as cellular membrane sorting
and trafﬁcking [62], and signal transduction [63] have been implicated
to these putative domains. In addition, membrane cholesterol has been
shown tomodulate the entry of pathogens to host cells [64]. It would be
interesting to compare to what extent 7- and 8-DHC could mimic
cholesterol in this regard. It has been previously reported using a
number of approaches thatmembrane domains formed by 7-DHC differ
with those formed by cholesterol in protein composition [65], packing
[66] and stability [67–69]. In addition, model membranes mimicking
SLOS membranes have been reported to exhibit atypical membrane
organization [23] and curvature [70]. It is therefore possible that mere
replacement of cholesterol with 7-DHC may signiﬁcantly affect aspects
of membrane organization such as near neighbor interactions (7-DHC is
more polar than cholesterol) and accessible surface area. Interestingly, it
has been reported that the activity of inward-rectiﬁer K+ channels is
modulated even by optical isomers of cholesterol thereby exemplifying
the speciﬁcity of interaction [71].
Dietary cholesterol has been proposed as a potential therapy in the
treatment of SLOS and currently a lot of research is focused on
developing a formula as food supplement for SLOS patients [33]. We
have metabolically replenished cholesterol in cells pre-treated with AY
9944 with serum and found that the ligand binding activity of the
human serotonin1A receptor could be recovered to a signiﬁcant extent
(Fig. 7B). Metabolic replenishment of cholesterol is relevant since the
only feasible treatment for SLOS patients is regular intake of dietary
cholesterol. It has been reported earlier that administration of dietary
cholesterol can partially reverse some of the behavioral abnormalities
[39]. It is possible that the impaired function of receptors such as theserotonin1A receptor in SLOS patients could be regained to some extent
after cholesterol administration. Taken together, our results could be
potentially useful inunderstanding themolecular basis that underlie the
pathophysiology of this disorder and could provide novel insight in
formulating future treatment for the disease.
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